Renal allograft recipients (RARs) receive immunosuppressive therapy over long periods of time and have an increased incidence of cutaneous neoplasia, particularly those with a long graft life or high sun exposure (Arends et al, 1990; Benton and Arends, 1996) . Allograft recipients (mainly women) are especially susceptible to human papillomavirus (HPV)-related anogenital tract neoplasia, which may be life-threatening (Alloub et al, 1989) . The skin neoplasms form part of a spectrum, encompassing viral warts showing dysplasia, actinic or verrucous keratoses displaying various viral architectural features or epidermal dysplasia and sometimes in topographical continuity with intraepidermal carcinoma (IEC) and invasive squamous cell carcinoma (SCC) . In contrast to anogenital cancers, 70-80% of which contain HPV 16 or 18 DNA, and to the skin cancers seen in epidermodysplasia verruciformis (EV), 90% of which contain HPV 5 or 8 DNA (Orth, 1987; Arends et al, 1990 Arends et al, , 1993 Pfister, 1992) , the results of HPV DNA detection studies in cutaneous SCCs from RARs show little consistency either in the frequency or viral type of HPV DNA found (Benton and Arends, 1996) . Some of this variation may be explained by small size of study sample or differences in substrates and techniques used, i.e. fresh or frozen tissue vs formalin-fixed paraffin-processed tissue (associated with poorer quality of extracted DNA, particularly for amplification of longer DNA fragments) (Wright and Manos, 1990) , dot blotting vs Southern hybridization or PCR techniques and, finally, the different ranges of HPV probes or PCR primers used.
Early studies were small and focused on HPV types 5 and 8 to determine whether skin cancers of RARs resembled those of EV patients. These studies reported the detection of HPV 5 and 8 in small numbers of cases that often included highly selected individuals, such as patients with multiple SCCs (Lutzner et al, 1980 (Lutzner et al, , 1983 Van der Leest et al, 1987; Barr et al, 1989; Blessing et al, 1990) . Negative results were reported in a number of studies; many are explicable by the use of less than ideal substrates, such as DNA from formalin-fixed tissue or suboptimal techniques, such as reverse blotting or dot-blot hybridization (Rudlinger and Grob, 1989; Blessing et al, 1990; Dyall-Smith et al, 1991; Smith et al, 1993; McGregor et al, 1994) , or the use of PCR with LI consensus primers that were designed primarily for detection of anogenital rather than cutaneous HPV types. These factors may account for negative results when looking for low copy numbers of cutaneous and EV types of HPV DNA using poor-quality substrate.
Recently, more sensitive techniques have detected a wide variety of HPV types, including uncharacterized HPV types, in skin cancers from RARs. In situ hybridization, Southern hybridization and PCR techniques detected HPV DNA in 37-54% SCCs from RARs, including anogenital, cutaneous and EV types of HPV (Muller et al, 1989; Eliezri et al, 1990; Euvrard et al, 1991;  Soler et al, 1992; Stark et al, 1994a) . Uncharacterized HPV types have been found in benign and malignant skin tumours using either degenerate PCR primers (Shamanin et al, 1994) , multiple complementary sets of consensus PCR primers (Tieben et al, 1994) or nested PCR assays (Berkhout et al, 1995) . The nested PCR approach detected HPV in 81% SCCs from RARs, including a wide spectrum of known and novel EV types of HPV (Berkhout et al, 1995) . It appears that, as HPV diagnostic technology for a broad spectrum of HPV types has improved, the reported prevalence of HPV DNA in SCCs from RARs has crept upwards and currently stands at around 80%. Here, we present data from a clinicopathological survey of RARs in south-east Scotland. This showed a widely disparate susceptibility to cutaneous malignancy among RARs, with evidence of concomitant variation in HPV DNA prevalence in their skin neoplasms. This suggests an important source of bias that may affect small studies and provides an explanation for the reported variation in HPV DNA prevalence and the wide range of viral types in other studies. specific HPV types 1, 2, 5, 8, 6b, 11, 16 and 18 (Arends et al, 1991; Stark et al, 1994a .
Immunocytochemical and mutational analysis of p53
Immunocytochemistry was performed on 3-jim sections of PLPDand formalin-fixed tissue, using the mouse anti p53 monoclonal antibodies MAb Do-7 (Vojtesek et al, 1992) and PAb 1801 (Banks et al, 1986 ) and a standard ABC horseradish peroxidase (HRP) technique (Dako, High Wycombe, Bucks, UK) as previously described (Purdie et al, 1991; Stark et al, 1994b) . Formalin-fixed tissue was treated with MAb Do-7 (1:100 dilution, overnight incubation) only, whereas PLPD-fixed material was treated with MAb Do-7 and PAb 1801 (1:100 dilution, 1-h incubation). Single-strand conformational polymorphism (SSCP) analysis for mutations in exons 5-8 of the p53 gene was performed on selected cases as previously described (Stark et al, 1994b) .
RESULTS

Clinicopathological survey of cutaneous lesions in
Tissue collection renal allograft recipients Biopsy samples were bisected longitudinally, half was placed immediately in PLPD (periodate lysine paraformaldehyde dichromate) (Holgate et al, 1986) or 10% formalin and fixed for 24 h at 4°C before paraffin embedding. Histological assessment and immunohistochemistry were carried out on sections prepared from paraffin-embedded material. The other half were snap frozen in liquid nitrogen and stored at -70°C to await DNA extraction and virological investigation.
DNA extraction and HPV detection Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM EDTA, 100 mm sodium chloride, 5 mM DTT, 1% sodium dodecyl sulphate (SDS), 1.5 mg ml proteinase K) then incubated at 37°C overnight; DNA extraction was carried out using a standard phenol-chloroform extraction technique (Sambrook et al, 1989) . Two methods were used to screen for the presence of HPV DNA (Stark et al, 1994a Seven high-susceptibility patients received immunosuppressive therapy based primarily on azathioprine, and one received cyclosporin A, but this reflected the availability of immunosuppressive drugs at the time of transplantation (cyclosporin A was introduced in 1984/85). Insufficient time has elapsed for valid comparisons to be made between patients receiving azathioprine and those treated with cyclosporin A, although no significant differences were found between the two regimens at 4 years (Bunney et al, 1990) . Furthermore, drug doses have been modified over this extended study period, as has advice given to patients regarding protection against sun exposure. The ranges of patients' ages and sun-exposure ratings between the different susceptibility groups overlap to such an extent that, given the small numbers of patients involved, no definite pattern of variation emerges. 38 RARs with a graft life of <15 years revealed no apparent differences in the prevalences of HPV DNA ( Table 2) . The group of patients with graft lives of >15 years included five high-susceptibility patients. The remaining three high-susceptibility patients had graft lives of 8-10 years. The median graft lives for the three patient groups were similar, as were their median ages (Tables 1  and 3 ). Despite the small numbers of patients concerned, these data suggest that long graft life is not the only determinant of the highsusceptibility phenotype, although the passage of time appears to be required for its expression. Thus, it is possible that some of the currently regarded ' . The IECs and SCCs examined were collected from 18 RARs. Control samples were collected over the same period and included 103 biopsies from immunocompetent patients (ICPs), including 48 with either IEC or SCC; these patients were, on average, 20 years older (mean age 75 years) than RARs with similar lesions (mean age 54 years). All of these lesions were subjected to HPV DNA detection by both low-stringency Southern hybridization analysis, capable of detecting almost all of HPV types 1-20, and PCR assays specific for HPV types 1, 2, 5, 8, 6b, 11, 16 and 18, as previously described (Arends et al, 1991; Stark et al, 1994a) . These analyses showed a range of different HPV types within the spectrum of skin neoplasms, including several of unknown HPV type detected by low-stringency Southern hybridization analysis, but no specific pattern or combination of HPV types in any one lesion (Table 2) . Susceptibility, susceptibility to development of cutaneous malignancy, high susceptibility defined histopathologically as . 4 IEC/SCC; intermediate susceptibility defined as 1-3 IEC/SCC or > 3 keratoses (including those with moderate or severe dysplasia within keratoses); low, low susceptibility defined as non-dysplastic warts or 1-3 keratoses (showing mild/moderate dysplasia), including clinically observed, non-biopsied keratoses with no IECs and no SCCs over a period of at least 10 years after transplantation. Malignant histology (lesions up to the end of 1994 included): IEC + SCC, combined total of cutaneous malignancies including intraepidermal carcinomas (IEC) and squamous cell carcinomas (SCC). Anogenital or aggressive skin lesions, see text for details.
The overall prevalences of HPV DNA are shown in Figure 1 for seven high-susceptibility patients, 23 intermediate-or lowsusceptibility patients (these two groups were combined because of small specimen numbers of keratoses for analysis) and 53 immunocompetent patient controls. HPV DNA prevalence was 50% in keratoses (8/16), 45% in IECs (10/22) and 56% in SCCs (15/27) from the high-susceptibility RARs, and these were greater than those from either intermediate-or low-susceptibility RARs -36% in keratoses (5/14 from both intermediate-and low-susceptibility RARs), 33% in IECs (3/9 from intermediate-susceptibility RARs) and 0% in SCCs (0/2 from intermediate-susceptibility RARs) and were also greater than those seen in immunocompetent patients: 15% in keratoses (2/13), 20% in IECs (5/25) and 27% in SCCs (4/15). Statistical comparisons using the chi-squared test showed significant differences only for HPV DNA prevalence in keratoses from the high-susceptibility subset compared with that in immunocompetent patients' keratoses (P<0.05), although an interesting, but not statistically significant, trend was seen in the comparison of the differences between HPV prevalences in the three groups of SCCs (high-susceptibility subset, intermediate-susceptibility subset and immunocompetent patients) (P=0.0875); the small numbers of cases limited the power of this analysis. There may be some under-reporting of HPV prevalence using this combination of low-stringency Southern hybridization analysis and specific PCR assays as only 9/14 viral warts from RARs were shown to contain HPV DNA using these methods, although this did increase to 14/19 (74%) if viral warts from immunocompetent patients were included.
Accumulation of p53 protein in skin neoplasms
Accumulation of the p53 protein, a tumour suppressor involved in the response to DNA damage, was analysed in a large subset of these specimens from different susceptibility groups. One hundred and twenty-eight biopsies of skin tumours from RARs and 75 from ICPs were screened for both p53 immunoreactivity and the presence of HPV DNA (Stark et al, 1994b) . Because of the limitations of p53 immunostaining, single-strand conformational polymorphism (SSCP) analysis of exons 5 to 8 of the p53 gene was used in 28 malignancies (IECs and SCCs) and detected p53 mutations in 5/9 (56%) lesions with widespread p53 immunostaining (>50% of tumour cells), 1/6 (17%) lesions with p53 staining occurring in 10-50% of cells and none when <10% cells were stained (Stark et al, 1994b (Alloub et al, 1989; Kelly et al, 1991) and also with a higher risk of anal HPV infection and anal neoplasia in RARs than controls (Ogunbiyi et al, 1994) .
DISCUSSION
Despite the relatively small number of cases in the susceptibility groups, the overall pattern of data from this clinicopathological survey suggests that some RARs may have either an increased susceptibility to persistent HPV infection, with an increased risk of development of multiple malignancies of the skin and anogenital tract, or some other mechanism of increased susceptibility to cutaneous and anogenital malignancy. In contrast, those RARs with a low susceptibility to skin malignancies also have a very low incidence of anogenital neoplasia, observed over long periods of follow-up, which may relate to a low level of carriage of HPV.
There are several possible reasons for a high susceptibility to HPV-associated neoplasia, including effects of certain combinations of MHC molecules that may modulate the immune response to HPV, either to most HPV types or to specific HPV types (Wank and Tomssen, 1991; Bouwes-Bavinck et al, 1993; Ellis et al, 1995) , genetically determined immunosuppressive effects of UV radiation acting locally (Yoshikawa et al, 1990) , variations in the response of the immune system to immunosuppressants and genetically determined differences in susceptibility to cutaneous malignancy per se. Alternatively, there may be abnormal interactions between host cells and HPV genomes which influence their replication and expression, and this may lead to differences in the efficiency of intracellular control of HPV activity (zur Hausen, 1994 (zur Hausen, , 1995 . Variations in HPV activity may be important in modulating the levels of HPV-induced cellular proliferation or apoptosis , allowing HPVs to act as tumour promoters as previously suggested by zur Hausen (1986) . In this way, HPVs may drive neoplastic progression by forcing cell replication or by suppressing apoptosis, which in turn may fix DNA mutations induced by UV radiation or other mutagens. Hence, in high-or intermediate-susceptibility patients, it is possible that increased susceptibility to HPV infection or reduced intracellular control of viral activity may allow HPVs to be more active promoters of carcinogenesis of the squamous epithelium of both skin and anogenital region. In such individuals, many different HPV types may have a common promoter-like effect, explaining the lack of an HPV type-specific relationship with RAR-associated skin cancer.
Variations in both the HPV types involved and patient susceptibility contribute to a complex situation in which it is difficult to determine the true prevalence of a wide range of HPV types in skin tumours in immunosuppressed transplant recipients. The difficulty is compounded if small numbers of cases are studied with possible distortions of the ratios of patients with high, intermediate or low susceptibility or if insufficiently broad-spectrum HPV type detection techniques are used. This may be particularly important as RARs appear to harbour a high proportion of unusual HPV types in their skin tumours (Shaminin et al, 1994 (Shaminin et al, , 1996 Tieben et al, 1994 Tieben et al, , 1995 , and this seems to be reflected in the significant number of lesions containing HPV DNA of unknown type seen in this study. These limitations are relevant to the design and data interpretation of all investigations into the risk factors involved in immunosuppression-associated neoplasia.
This study emphasizes the need for frequent screening for skin tumours in transplant recipients, and this need for surveillance is recognized by other groups (Leigh and Glover, 1995; London et al, 1995) . In particular, these data emphasize the clinical importance of screening for potentially lethal anogenital neoplasms in highsusceptibility RARs. The intermediate-susceptibility RARs are at a lower risk of anogenital malignancy, but for the individual patient this is a significant risk nevertheless. Furthermore, a proportion of intermediate-susceptibility RARs may progress to the high-susceptibility subset in time.
